SomnoMed Limited (SOMNF) Fair Value & Analysis
Healthcare · US · Market cap $93.3M
SomnoMed Limited
SOMNF · US
Fair value as of: Jul 18, 2026
From 15 valuation models · updated 5 days ago
Price vs Fair Value (12 months)
12‑month range $0.1500 – $0.5100 · fair‑value band $0.2125 – $0.3315 · the $0.4500 price screens above the $0.2720 fair value. As of Jul 18, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
SomnoMed Limited (SOMNF) currently trades at $0.4500, while our model-based Fair Value estimate is $0.2720, implying the stock looks roughly 39.6% overvalued today. We read business quality at 43/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, SomnoMed Limited generated revenue of $119M at a net margin of -2.2%. Revenue grew 13.0% year over year. It earns a return on equity of -5.3%. The balance sheet holds a net cash position of $9.3M. Fundamentals as of Jul 18, 2026
Our scenario range runs from $0.2125 (bear case) to $0.3315 (bull case); at $0.4500, the current price sits above that range. The share trades about 12% below its 52-week high and 2% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -27% fair-value upside, at -40%, SOMNF screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 18, 2026. TTM = trailing twelve months.
About the company
SomnoMed Limited, together with its subsidiaries, produce and sells devices for the oral treatment of sleep related disorders in the Asia Pacific region, North America, and Europe. It provides SomnoDent Avant, as well as SomnoDent Classic, SomnoDent Flex, and SomnoDent Fusion are offered for the treatment of obstructive sleep apnea. The company also offers SomMorning Repositioner, a product designed to help return patient's mandible back to its pre-treatment centric position; SomnoBrux splint, a custom fit, acrylic splint for patient's upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs, which are cleaning tablets to clean oral appliances. SomnoMed Limited was incorporated in 1987 and is headquartered in Crows Nest, Australia.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
SomnoMed Limited reported revenue of $111M in FY2025 versus $62.7M in FY2021, a compound +15.5%/yr. Reported net income was −$3.5M in FY2025.
Is SOMNF fairly valued? → Check now
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 18, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $89.17 | $70.59 | -21% |
| Stryker Corporation SYK | $308.84 | $187.83 | -39% |
| Medtronic plc MDTC34 | R$213.40 | R$31.21 | -85% |
| Boston Scientific Corporation B1SX34 | R$229.30 | R$43.33 | -81% |
| Edwards Lifesciences Corporation EWL | €74.82 | €32.56 | -56% |
| Siemens Healthineers AG SEMHF | $40.29 | $47.96 | +19% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥144.39 | ¥105.08 | -27% |
| STERIS plc S1TE34 | R$52.14 | R$39.50 | -24% |
| Zimmer Biomet Holdings Z1BH34 | R$116.16 | R$85.57 | -26% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is SomnoMed Limited (SOMNF) undervalued?
What is the fair value of SOMNF?
What is the quality score of SOMNF?
What is the revenue of SomnoMed Limited (SOMNF)?
What is the net profit margin of SOMNF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full SomnoMed Limited analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.